sunobinop

Sunobinop is a potent, selective, orally administered small molecule partial agonist of the nociceptin/orphanin FQ peptide (NOP) receptor. It exhibits high affinity and functional selectivity for the NOP receptor, with minimal activity at other opioid receptors—acting as a low-affinity antagonist at mu and kappa opioid receptors and a weak partial agonist at delta opioid receptors. Sunobinop is being developed primarily for the treatment of insomnia, alcohol use disorder (AUD), interstitial cystitis, and overactive bladder syndrome. In preclinical models and clinical studies, it has demonstrated efficacy in promoting non-REM sleep without significant effects on learning, memory, reward pathways, respiration or intestinal transit. The drug is rapidly absorbed after oral administration with a short half-life suitable for once-daily nighttime dosing; it is predominantly eliminated unchanged via renal excretion. Sunobinop was originally discovered by Purdue Pharma/Shionogi and is currently under development by Imbrium Therapeutics[1][3][4][5][6][7].

Other names

sunobinop tosylate